Childhood Arthritis

You have full text access to this OnlineOpen article

Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment

  1. Susan Kim†,*,
  2. Moussa El-Hallak†,
  3. Fatma Dedeoglu,
  4. David Zurakowski,
  5. Robert C. Fuhlbrigge,
  6. Robert P. Sundel

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24571

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 6, pages 1825–1830, June 2009

Additional Information

How to Cite

Kim, S., El-Hallak, M., Dedeoglu, F., Zurakowski, D., Fuhlbrigge, R. C. and Sundel, R. P. (2009), Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis & Rheumatism, 60: 1825–1830. doi: 10.1002/art.24571

Author Information

  1. Children's Hospital Boston, Boston, Massachusetts

  1. †

    Drs. Kim and El-Hallak contributed equally to this work.

*Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 9 MAR 2009
  4. Manuscript Received: 4 JUN 2008

Funded by

  • NIH. Grant Numbers: T32-AI-007512, KL2-RR-025757-01

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (115K)

REFERENCES

  • 1
    Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr 1964; 64: 101–31.
  • 2
    Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52: 3570–8.
    Direct Link:
  • 3
    Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27: 2498–503.
  • 4
    Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 541–9.
    Direct Link:
  • 5
    Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103: 882–8.
  • 6
    Cimaz R. Osteoporosis in childhood rheumatic diseases: prevention and therapy. Best Pract Res Clin Rheumatol 2002; 16: 397–409.
  • 7
    Pachman LM, Maryjowski MC. Juvenile dermatomyositis and polymyositis. Clin Rheum Dis 1984; 10: 95–115.
  • 8
    Sallum AM, Kiss MH, Sachetti S, Resende MB, Moutinho KC, Carvalho Mde S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002; 60: 889–99.
  • 9
    Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87: 70–86.
  • 10
    Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47: 505–11.
  • 11
    Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344–7.
  • 12
    Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 7–15.
    Direct Link:
  • 13
    Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52: 2607–15.
    Direct Link:
  • 14
    Machin D, Cheung YB, Parmar M. Survival analysis: a practical approach. 2nd ed. New York: Wiley; 2006.
  • 15
    Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963–74.
  • 16
    Holland JF. Hopes for tomorrow versus realities of today: therapy and prognosis in acute lymphocytic leukemia of childhood. Pediatrics 1970; 45: 191–3.
  • 17
    Baum E, Sather H, Nachman J, Seinfeld J, Krivit W, Leikin S, et al. Relapse rates following cessation of chemotherapy during complete remission of acute lymphocytic leukemia. Med Pediatr Oncol 1979; 7: 25–34.
    Direct Link:
  • 18
    Donadieu J, Auclerc MF, Baruchel A, Leblanc T, Landman-Parker J, Perel Y, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group. Br J Haematol 1998; 102: 729–39.
    Direct Link:
  • 19
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30.
    Direct Link:
  • 20
    Progress against childhood cancer: the Pediatric Oncology Group experience. Pediatrics 1992; 89(4 Pt 1): 597–600.
  • 21
    Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001; 7: 899–905.
  • 22
    Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85–95.
  • 23
    Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894–8.
    Direct Link:
  • 24
    Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 59: 222–6.
    Direct Link:
  • 25
    National Cancer Institute. Common toxicity criteria. URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
View Full Article (HTML) Get PDF (115K)